Stockreport

Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline [Yahoo! Finance]

BioNTech SE - American Depositary Shares  (BNTX) 
PDF Neutral to Buy and boosted its price target from $115 to $142, highlighting the company's key position in oncology. According to the firm, BioNTech SE (NASDAQ:BNTX) stan [Read more]